NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Greenwich LifeSciences, Inc. (GLSI) Stock Analysis

Greenwich LifeSciences, Inc. (GLSI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GLSI

$15.95

+$0.32 (+2.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GLSI with… →

GLSI Key Statistics

As of Sep 4, 2026
Trading
Open
$15.45
Previous Close
$15.63
Day's Range
15.45–15.98
52-Week Range
7.78–34.10
Volume
65.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.46
Valuation
Market Cap
$234.12M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.59
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$19.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.68M
1-Year Return
+45.40%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
147.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GLSI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.08%
2025+87.09%
2024+6.75%
2023−30.79%
2022−37.53%
2021−33.29%
2020 (partial year)+629.40%

As of September 4, 2026.

GLSI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$19.36M—
2024$0.00−$17.41M—
2023$0.00−$8.89M—
2022$0.00−$7.83M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$19.45M−$19.36M—
2024$0.00—−$17.64M−$17.41M—
2023$0.00—−$9.33M−$8.89M—
2022$0.00—−$8.04M−$7.83M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GLSI Valuation vs Biotechnology Median

Median of 656 stocks
MetricGLSIBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Greenwich LifeSciences, Inc. (GLSI) at $234.12M. The company sits in the Healthcare sector, in the Biotechnology industry.

Over the past 52 weeks the price has ranged from $7.78 to $34.10. GLSI last closed at $15.95 on September 4, 2026. That is +$0.32 (+2.05%) against the previous close. The latest close sits 105.01% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $19.36M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.59.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.46. Annualized volatility over the trailing 5 years is 80.85%. The trailing one-year price return is +45.40%. Measured over 5 years, that is −18.35% a year compounded.

Growth & Income

No dividend is on file for GLSI.

The strongest complete calendar year on file is 2025 at +87.09%; the weakest is 2022 at −37.53%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the price is −24.08%.

Peer Comparison

Greenwich LifeSciences, Inc. (GLSI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Greenwich LifeSciences, Inc. GLSI $234.12M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Greenwich LifeSciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Visit website →